Skip to main content
SpringerLink
Log in
Book cover

Complement Therapeutics

  • Book
  • © 2013

Overview

Editors:
  1. John D. Lambris

    1. Medicine, University Of Pennsylvania Department Of Pathology Laboratory Of, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. V. Michael Holers

    1. University of Colorado School of Medicin, Aurora, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Daniel Ricklin

    1. Department of Pathology & Laboratory Med, University of Pennsylvania School of Med, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Proceedings from the 5th International Complement Theraputics Conference
  • Part of the Aegean Conferences series
  • Incorporates cutting-edge research and showcases methods developed and perfected in the last decade

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 735)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (21 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Progress and Trends in Complement Therapeutics

    • Daniel Ricklin, John D. Lambris
    Pages 1-22

  3. Inhibition of the Serine Proteases of the Complement System

    • Péter Gál, József Dobó, László Beinrohr, Gábor Pál, Péter Závodszky
    Pages 23-40

  4. The Role of MASP-1/3 in Complement Activation

    • Hideharu Sekine, Minoru Takahashi, Daisuke Iwaki, Teizo Fujita
    Pages 41-53

  5. Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE

    • Nibhriti Das, Bintili Biswas, Rohan Khera
    Pages 55-81

  6. DAF as a Therapeutic Target for Steroid Hormones: Implications for Host–Pathogen Interactions

    • Bogdan Nowicki, Stella Nowicki
    Pages 83-96

  7. Targeting gC1qR Domains for Therapy Against Infection and Inflammation

    • Berhane Ghebrehiwet, Jolyon Jesty, Rama Vinayagasundaram, Uma Vinayagasundaram, Yan Ji, Alisa Valentino et al.
    Pages 97-110

  8. The Alternative C5a Receptor Function

    • Hiroshi Nishiura
    Pages 111-121

  9. The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood

    • O.-L. Brekke, C. Waage, D. Christiansen, H. Fure, H. Qu, John D. Lambris et al.
    Pages 123-136

  10. CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Specific Complement Modulation

    • V. Michael Holers, Bärbel Rohrer, Stephen Tomlinson
    Pages 137-154

  11. Paroxysmal Nocturnal Hemoglobinuria and the Complement System: Recent Insights and Novel Anticomplement Strategies

    • Antonio M. Risitano
    Pages 155-172

  12. Defective Complement Action and Control Defines Disease Pathology for Retinal and Renal Disorders and Provides a Basis for New Therapeutic Approaches

    • Peter F. Zipfel, Nadine Lauer
    Pages 173-187

  13. C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Findings in 21 Families

    • Constantinos Deltas, Daniel Gale, Terence Cook, Konstantinos Voskarides, Yiannis Athanasiou, Alkis Pierides
    Pages 189-196

  14. Complement-Targeted Therapeutics in Periodontitis

    • George Hajishengallis, John D. Lambris
    Pages 197-206

  15. Complement System Activation in Cardiac and Skeletal Muscle Pathology: Friend or Foe?

    • Maro Syriga, Manolis Mavroidis
    Pages 207-218

  16. Innate Immunity as Orchestrator of Bone Marrow Homing for Hematopoietic Stem/Progenitor Cells

    • Mariusz Z. Ratajczak, ChiHwa Kim, Janina Ratajczak, Anna Janowska-Wieczorek
    Pages 219-232

  17. Complement-Mediated Microvascular Injury Leads to Chronic Rejection

    • Mohammad A. Khan, Mark R. Nicolls
    Pages 233-246

  18. Targeting Complement at the Time of Transplantation

    • Steven Sacks, Julia Karegli, Conrad A. Farrar, Elham Asgari, Wilhelm Schwaeble, Wuding Zhou et al.
    Pages 247-255

  19. Evaluation of the Blood Compatibility of Materials, Cells, and Tissues: Basic Concepts, Test Models, and Practical Guidelines

    • Kristina N. Ekdahl, Jaan Hong, Osama A. Hamad, Rolf Larsson, Bo Nilsson
    Pages 257-270

  20. Noninvasive Detection of Complement Activation Through Radiologic Imaging

    • Joshua M. Thurman, Bärbel Rohrer
    Pages 271-282
Back to top

Keywords

About this book

This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. In addition, complement is often involved in adverse immune reactions to biomaterials, cell and organ transplants or drug delivery systems. Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials.

 

The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the molecular and functional description of complement targets to the presentation of novel inhibitors, improved treatment strategies as well as examples of disease models and clinical applications. The broad and up-to-date overview on a highly versatile and dynamic field renders this book an indispensable source of information for researchers and clinicians dealing with therapeutic and disease-related aspects of the human complement system.

Editors and Affiliations

  • Medicine, University Of Pennsylvania Department Of Pathology Laboratory Of, Philadelphia, USA

    John D. Lambris

  • University of Colorado School of Medicin, Aurora, USA

    V. Michael Holers

  • Department of Pathology & Laboratory Med, University of Pennsylvania School of Med, Philadelphia, USA

    Daniel Ricklin

About the editors

Progress and Trends in Complement Therapeutics.- Inhibition of the serine proteases of the complement system.- The role of MASP-1/3 in complement activation.- Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.- DAF as a therapeutic target for steroid hormones: implications for host pathogen interactions.- Targeting gC1qR domains for therapy against infection and inflammation.- The Alternative C5a Receptor Function.- The effects of selective complement- and CD14-inhibition on the E. coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and tissue factor functional activity in human whole blood.- CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Specific Complement Modulation.- Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anti-complement strategies.- Defective Complement Action and Control Defines Disease Pathology forRetinal and Renal Disorders and Provides a Basis for new Therapeutic Approaches.- C3 Glomerulonephritis/CFHR5 Nephropathy is an endemic disease in Cyprus: Clinical and molecular findings in 21 families.- Complement-targeted therapeutics in periodontitis.- Complement system activation in cardiac and skeletal muscle pathology: Friend or foe?.- Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/progenitor cells.- Complement-mediated microvascular injury leads to chronic rejection.- Targeting complement at the time of transplantation.- Evaluation of the blood compatibility of materials, cells and tissues: Basic concepts, test models and practical guidelines.- Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics and Therapeutics.- Complement in Action: A Review of Patent Trends From 1976 through 2011.

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation